Simeprevir for hepatitis C virus

Nurse Pract. 2014 Sep 18;39(9):10-2. doi: 10.1097/01.NPR.0000452985.51256.53.

Authors

Shelley Hutcheson¹, Olga M Klibanov

Affiliation

¹ Shelley Hutcheson is a pharmacy student and Olga M. Klibanov is a professor of pharmacy at Wingate University, Wingate, N.C.

PMID: 25140845
DOI: 10.1097/01.NPR.0000452985.51256.53

No abstract available

MeSH terms

Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
Drug Approval
Hepatitis C / drug therapy*
Heterocyclic Compounds, 3-Ring / pharmacology
Heterocyclic Compounds, 3-Ring / therapeutic use*
Humans
Simeprevir
Sulfonamides / pharmacology
Sulfonamides / therapeutic use*
United States
United States Food and Drug Administration

Substances

Antiviral Agents
Heterocyclic Compounds, 3-Ring
Sulfonamides
Simeprevir